Abstract
Breast cancer (BC) is the most common cause of cancer-related death in young women, but stages I to III are highly curable regardless of age. Classically HER2-positive disease has been considered a poor prognosis but few studies have evaluated the impact of anti-HER2 treatments. Knowing the risk of recurrence and time to recurrence can determine follow-up and time to follow, key issues for a population with a potentially long survival.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
